
|Articles|July 1, 2004
POINT LAUNCHES STUDY
Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
4
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
5














